Routine Colonoscopies Still Elude Too Many New Yorkers, Especially Among Latino Residents

Routine screening for colorectal cancer remains a matter of life and death for New York’s Hispanic communities.

“Prevention is better than cure” may sound trite, but for colorectal cancer, it is as literal as medicine gets. In New York City, colorectal cancer is now the second leading cause of cancer deaths among Hispanics—a stark, if underappreciated, epidemic quietly stalking a population larger than many small countries. Data from the American Cancer Society show that Latinx New Yorkers are not only more likely to be diagnosed with colorectal cancer, but frequently do so at more advanced, and less treatable, stages.

This month, as part of a national awareness campaign, clinicians and advocates are urging New Yorkers—especially Hispanics—to take simple, evidence-based preventive steps: schedule screenings, embrace healthier living, and keep an ear cocked for bodily warning signs. The message is blunt, but necessary. Dr. Richard Kops, a veteran gastroenterologist attached to Healthfirst, underscores what is patently clear in his practice: most tragic outcomes could have been headed off by timely detection.

Colorectal cancer, affecting the colon or rectum, is especially insidious because early stages rarely present symptoms. Yet when found early, more than 90% of cases can be effectively treated, turning a grim diagnosis into a manageable, often curable, condition. Nonetheless, large disparities persist; one study published by New York’s Department of Health in 2023 found that Hispanics comprise nearly a quarter of local late-stage cases—verging on twice their share of the city’s population.

The upshot is as sobering as statistics get. In many boroughs with majority Latino populations—such as the Bronx and northern Queens—cancer registries show pronounced lags in routine screenings. Colonoscopies, the gold standard of detection, remain worryingly underutilized, stunted by lack of awareness, patchy insurance coverage, and, in some quarters, persistent cultural taboos regarding invasive procedures.

New York’s public health agencies have pulled familiar levers, with intermittent bursts of outreach, but structural obstacles prove stubborn. Healthfirst and other insurers tout preventive benefits, yet uptake stays puny compared to the need. Language remains a barrier in a city replete with newly arrived immigrants; many are less likely to have regular primary care visits or insurance consistent with preventive care. Half-hearted adherence to screening guidelines—typically beginning at age 45—is, by now, a known liability.

There is evidence that the pandemic has deepened these gaps. Routine cancer screenings across the city plummeted by as much as 30% in 2020–2021, per analysis by NYC Health + Hospitals. The catching-up has proved tepid—perhaps understandable, given economic pressures and the psychic weight of COVID-19 on vulnerable populations.

For New Yorkers, the economic and social knock-ons are far from trivial. Colorectal cancer strikes working-age adults with unnerving regularity; late diagnosis portends costlier, prolonged treatment and lost productivity. Family caregivers—often themselves juggling precarious employment—face additional fiscal and emotional strains. Employers, meanwhile, must reckon with avoidable workforce attrition.

A patchwork of prevention and its discontents

Politically, the disparities in colorectal cancer outcomes feed into unrelenting debates about health equity in America’s largest city. Despite a nominal guarantee of coverage for preventive care under both Medicare and the Affordable Care Act, the on-the-ground reality remains uneven. Community clinics try valiantly to plug the gaps, but are too often under-resourced and overwhelmed. Meanwhile, local officials face criticism for the cyclical nature of their campaigns—high-visibility initiatives that fade once annual awareness months pass.

By any global standard, New York’s predicament is not unique. Despite robust national guidelines from the U.S. Preventive Services Task Force—mirrored in Canada and parts of Western Europe—uptake among minorities lags unsatisfactorily. Some nations, notably Japan, employ aggressive annual fecal screening with impressive results; the United Kingdom, likewise, has invested heavily in outreach with a demonstrable narrowing of class and ethnic disparities. The U.S. approach, fragmented between public and private insurance and reliant on primary care gatekeepers, yields patchier returns.

The evidence base is unambiguous. Three straightforward measures—regular screenings (by colonoscopy or validated stool tests), adherence to healthy diet and exercise, and prompt attention to anomalous symptoms—would reduce incidence and mortality significantly. Yet, as so often in public health, the challenge lies more in prosaic execution than scientific ambiguity.

We find some cause for optimism in New York’s recent pilot schemes, which enlist trusted voices in the Hispanic community—faith leaders, neighborhood pharmacists, even local bodegueros—to disseminate information and normalize screening. There are glimmers of progress: Healthfirst and other insurers report a modest uptick in preventive screening rates over 2023, albeit from a low base.

Yet the scale of the task dwarfs these incremental advances. Public health will not be won by pamphlets alone. Real gains will require well-funded, sustained multi-lingual outreach, better integration of community health workers, and a determined effort to embed prevention in the patchwork of New York’s insurance and healthcare ecosystems. Even then, shifting stubborn attitudes across generations—living as much in superstition as in data—will demand consistent, non-patronizing engagement.

Colorectal cancer need not exact such a grim toll. With effective, culturally attuned prevention, its impact could be relegated from a leading killer to a managed nuisance—much as vaccines did for polio. New York’s leaders would do well to heed the lesson: the most powerful medical interventions are often, in execution, the dullest. Prosaic though it may be, a scheduled colonoscopy may yet save more New York lives than a glittering hospital in midtown. ■